Measurable Residual Disease in Clinical and Regulatory Decision Making

THE EUROPEAN Hematology Association-European Medicines Agency (EHA2025-EMA) Joint Symposium on minimal residual disease (MRD), which took place at the EHA2025 Congress in Milan, Italy, explored its critical role in clinical and regulatory decision-making across various haematologic malignancies. Experts and patient advocates discussed advances in MRD detection, its impact on treatment strategies, and the challenges of standardisation and acceptance in both clinical practice and regulatory frameworks. While this article refers to ‘minimal residual disease’, the term ‘measurable residual disease’ is increasingly being used instead.